Financial Performance - The company's operating revenue for Q3 2023 was approximately CNY 347.04 million, representing a year-on-year increase of 58.28%[6]. - The net profit attributable to shareholders for Q3 2023 was a loss of CNY 327.23 million, with a cumulative loss of CNY 1.03 billion for the year-to-date[6]. - Total operating revenue for the first three quarters of 2023 reached RMB 769,470,314.65, a significant increase of 35% compared to RMB 569,635,902.97 in the same period of 2022[20]. - Net profit for the first three quarters of 2023 was a loss of RMB 1,030,585,859.60, worsening from a loss of RMB 688,219,233.92 in the same period of 2022[21]. - The company experienced a total comprehensive loss of RMB 1,038,494,630.57 in 2023, compared to a loss of RMB 680,108,752.02 in 2022[22]. Research and Development - Research and development expenses totaled CNY 317.52 million in Q3 2023, an increase of 49.16% compared to the same period last year[7]. - The ratio of R&D expenses to operating revenue was 91.49%, a decrease of 5.59 percentage points year-on-year[7]. - The company continues to invest heavily in R&D to support its drug pipeline and clinical trials, leading to increased operational costs[12]. - Research and development expenses increased to RMB 857,977,852.40 in 2023, compared to RMB 662,541,383.59 in 2022, marking a 29.5% rise[21]. Assets and Liabilities - Total assets at the end of Q3 2023 were approximately CNY 5.51 billion, down 8.42% from the end of the previous year[7]. - The equity attributable to shareholders decreased by 20.56% year-on-year, amounting to approximately CNY 3.96 billion[7]. - The company's total assets as of September 30, 2023, amount to ¥5,514,357,338.62, a decrease from ¥6,021,189,680.87 at the end of 2022[19]. - Current assets total ¥2,235,196,172.88, down from ¥3,212,137,039.58 in the previous year[18]. - The total liabilities as of September 30, 2023, are ¥1,558,115,861.03, compared to ¥1,040,890,051.43 in the previous year[19]. Cash Flow - The company reported a net cash flow from operating activities of CNY -1.11 billion for the year-to-date[7]. - Cash flow from operating activities showed a net outflow of RMB 1,114,762,180.68 in 2023, compared to a net outflow of RMB 1,080,292,854.28 in 2022[23]. - Cash inflow from investment activities totaled RMB 846,955,292.55 in 2023, while cash outflow was RMB 1,767,323,954.74, resulting in a net outflow of RMB 920,368,662.19[24]. - The company reported cash and cash equivalents at the end of Q3 2023 amounting to RMB 546,094,957.35, down from RMB 1,967,108,319.61 at the end of Q3 2022[24]. - The company has a total of ¥609,013,239.33 in cash and cash equivalents, down from ¥2,187,326,306.04[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,045[13]. - HKSCC NOMINEES LIMITED holds 189,566,228 shares, accounting for 34.83% of total shares[14]. Market Strategy - The increase in operating revenue was primarily driven by higher sales of injectable drugs, including TaiTasi and VidiXimab[11]. - The company is focusing on expanding its market presence and developing new products and technologies[16].
荣昌生物(09995) - 2023 Q3 - 季度业绩